Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma

被引:10
作者
Eleutherakis-Papaiakovou, Evangelos [1 ]
Gavriatopoulou, Maria [1 ]
Ntanasis-Stathopoulos, Ioannis [1 ]
Kastritis, Efstathios [1 ]
Terpos, Evangelos [1 ]
Dimopoulos, Meletios A. [1 ]
机构
[1] Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece
关键词
Elotuzumab; monoclonal antibody; pomalidomide; immunomodulatory drugs; multiple myeloma; treatment; LOW-DOSE DEXAMETHASONE; IMMUNOMODULATORY DRUGS IMIDS; OPEN-LABEL; PLUS POMALIDOMIDE; PHASE-I; LENALIDOMIDE; SURVIVAL; THERAPY; CARFILZOMIB; CELLS;
D O I
10.1080/14737140.2019.1685879
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Despite major advances in the therapeutic management of multiple myeloma (MM), it remains an incurable disease. Several combinations of monoclonal antibodies with novel agents are being investigated with promising results in order to prolong progression-free and overall survival. Areas covered: This paper aims to critically present available data from clinical trials investigating the combination of elotuzumab with pomalidomide and dexamethasone in refractory/relapsed MM patients and determine its current role in clinical practice. Expert opinion: Pomalidomide-based combinations with monoclonal antibodies have been shown to be effective in patients with MM who are refractory to or have relapsed following treatment with lenalidomide and/or a proteasome inhibitor (PI). These regimens seem to be more effective than the standard combination of pomalidomide with dexamethasone alone. Taking into consideration that the vast majority of MM patients will receive upfront treatment including a PI and lenalidomide in the near future, pomalidomide-based triplets, such as elotuzumab-pomalidomide-dexamethasone, will become the standard of care in the second line of therapy.
引用
收藏
页码:921 / 928
页数:8
相关论文
共 92 条
  • [1] Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
    Anderson, G
    Gries, M
    Kurihara, N
    Honjo, T
    Anderson, J
    Donnenberg, V
    Donnenberg, A
    Ghobrial, I
    Mapara, MY
    Stirling, D
    Roodman, D
    Lentzsch, S
    [J]. BLOOD, 2006, 107 (08) : 3098 - 3105
  • [2] [Anonymous], SCI MED HLTH
  • [3] The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma
    Awwad, Mohamed H. S.
    Kriegsmann, Katharina
    Plaumann, Julian
    Benn, Michael
    Hillengass, Jens
    Raab, Marc S.
    Bertsch, Uta
    Munder, Markus
    Weisel, Katja
    Salwender, Hans Juergen
    Haenel, Mathias
    Fenk, Roland
    Duerig, Jan
    Mueller-Tidow, Carsten
    Goldschmidt, Hartmut
    Hundemer, Michael
    [J]. ONCOIMMUNOLOGY, 2018, 7 (10):
  • [4] Darwinian evolution and tiding clones in multiple myeloma
    Bahlis, Nizar J.
    [J]. BLOOD, 2012, 120 (05) : 927 - 928
  • [5] Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
    Baz, Rachid C.
    Martin, Thomas G., III
    Lin, Hui-Yi
    Zhao, Xiuhua
    Shain, Kenneth H.
    Cho, Hearn J.
    Wolf, Jeffrey L.
    Mahindra, Anuj
    Chari, Ajai
    Sullivan, Daniel M.
    Nardelli, Lisa A.
    Lau, Kenneth
    Alsina, Melissa
    Jagannath, Sundar
    [J]. BLOOD, 2016, 127 (21) : 2561 - 2568
  • [6] Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study
    Berdeja, Jesus
    Jagannath, Sunday
    Zonder, Jeffrey
    Badros, Ashraf
    Kaufman, Jonathan L.
    Manges, Robert
    Gupta, Manish
    Tendolkar, Amol
    Lynch, Mark
    Bleickardt, Eric
    Paliwal, Prashni
    Vij, Ravi
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (03) : 129 - 138
  • [7] Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
    Biran, Noa
    Siegel, David
    Berdeja, Jesus G.
    Raje, Noopur
    Cornell, Robert Frank
    Alsina, Melissa
    Kovacsovics, Tibor
    Fang, Belle
    Kimball, Amy S.
    Landgren, Ola
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (07) : 794 - 802
  • [8] Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial
    Boyle, Eileen M.
    Leleu, Xavier
    Petillon, Marie-Odile
    Karlin, Lionel
    Doyen, Chantal
    Demarquette, Helene
    Royer, Bruno
    Macro, Margaret
    Moreau, Philippe
    Fostier, Karel
    Marie-Lorraine, Chretien
    Zarnitsky, Charles
    Perrot, Aurore
    Herbaux, Charles
    Poulain, Stephanie
    Manier, Salomon
    Beauvais, David
    Walker, Brian A.
    Wardell, Christopher P.
    Vincent, Laure
    Frenzel, Laurent
    Caillon, Helene
    Susanna, Schraen
    Dejoie, Thomas
    Avet-Loiseau, Herve
    Mohty, Mohamad
    Facon, Thierry
    Arnulf, Bertrand
    Dib, Mamoun
    Brechignac-Bureau, Sabine
    Godmer, Pascal
    Tempescul, Adrian
    Fohrer, Cecile
    Benboubker, Lotfi
    Voillat, Laurent
    Malfuson, Jean Valere
    Mariette, Clara
    Tiab, Mourad
    Rigaudeau, Sophie
    Jaccard, Arnaud
    Stoppa, Anne-Marie
    Eisenmann, Jean-Claude
    Rodon, Philippe
    Kolb, Brigitte
    Decaux, Olivier
    Onraed, Brigitte
    Attal, Michel
    Hulin, Cyrille
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (03) : 319 - 327
  • [9] Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
    Campbell, Kerry S.
    Cohen, Adam D.
    Pazina, Tatiana
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [10] SLAM Family Receptors and SAP Adaptors in Immunity
    Cannons, Jennifer L.
    Tangye, Stuart G.
    Schwartzberg, Pamela L.
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, VOL 29, 2011, 29 : 665 - 705